Emerging Trends in the Mitral Valve Disease Market, North America accounted for the largest market share

• CAGR: 8.8%
• Current Market Size: USD 2.5Billion
• Forecast Growing Region: APAC
• Largest Market: North America
• Projection Time: 2022 to 2031
• Base Year: 2021

The mitral valve disease market size was valued at $2.5 billion in 2021, and is estimated to reach $5.7 billion by 2031, growing at a CAGR of 8.8% from 2022 to 2031.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐒𝐚𝐦𝐩𝐥𝐞- https://www.alliedmarketresearch.com/request-sample/74863

𝐑𝐞𝐜𝐞𝐧𝐭 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 𝐢𝐧 𝐌𝐢𝐭𝐫𝐚𝐥 𝐕𝐚𝐥𝐯𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐌𝐚𝐫𝐤𝐞𝐭
In January 2020, Abbott received the CE Mark approval of Abbott's Tendyne Transcatheter Mitral Valve Implantation (TMVI) system used in the treatment of mitral regurgitation (MR) in patients who require a heart valve replacement and is now approved for use in Europe.

In September 2021, Abbott received the U.S. Food and Drug Administration (FDA) approval for Epic Plus and Epic Plus Supra Stented Tissue Valves. These new devices are based on Abbott's Epic surgical valve platform, which improve therapy options for people with aortic or mitral valve disease.
Divestment in Mitral Valve Disease Market

In June 2021, Corcym announced the launch of its operations globally, which is formed from the acquisition of the LivaNova Plc. heart valve business by Gyrus Capital. The new, independent, medical device company will be dedicated towards providing patients and heart surgeons with the best solutions to fight structural heart disease.
Investment in the Mitral Valve Disease Market

In March 2019, Edwards Lifesciences Corporation has announced two strategic transactions involving companies with structural heart disease technologies. The transaction involves a $35 million investment in an exclusive right to acquire Corvia Medical, Inc. and the acquisition of certain assets of Mitralign, Inc, a company that specializes in developing devices for the treatment of mitral valve regurgitation.

𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (374+ 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬: https://www.alliedmarketresearch.com/mitral-valve-disease-market/purchase-options

𝐍𝐞𝐰 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐢𝐧 𝐌𝐢𝐭𝐫𝐚𝐥 𝐕𝐚𝐥𝐯𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐌𝐚𝐫𝐤𝐞𝐭
In November 2021, Medtronic plc. presented early data for Intrepid transcatheter mitral valve replacement (TMVR) system in patients with severe, symptomatic mitral valve regurgitation (MR) utilizing the transfemoral access route. The data from first 5 patients enrolled in an Early Feasibility Study of the Intrepid Transfemoral System showed 100% survival and no stroke and none or trace MR in all implanted patients at 30 days.

𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐅𝐨𝐫 𝐒𝐭𝐚𝐤𝐞𝐡𝐨𝐥𝐝𝐞𝐫𝐬
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mitral valve disease market analysis from 2021 to 2031 to identify the prevailing mitral valve disease market opportunity.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the mitral valve disease market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global mitral valve disease market trends, key players, market segments, application areas, and market growth strategies.

𝐃𝐨 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲- https://www.alliedmarketresearch.com/purchase-enquiry/74863

𝐊𝐞𝐲 𝐌𝐢𝐭𝐫𝐚𝐥 𝐕𝐚𝐥𝐯𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬
Novartis AG
Labcor Laboratorios Ltda
Teva Pharmaceutical Industries Ltd.
Bayer AG
Artivion, Inc.
Braile Biomedica
Pfizer Inc.
Abbott Laboratories
Affluent Medical
Valcare Medical
Corcym UK Limited
Edwards Lifesciences Corporation
ShockWave Medical, Inc.
Zydus Lifesciences Limited
Medtronic plc

𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞 - https://www.alliedmarketresearch.com/mitral-valve-disease-market-A74388

𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 -
𝐀𝐧𝐞𝐬𝐭𝐡𝐞𝐬𝐢𝐚 𝐌𝐚𝐜𝐡𝐢𝐧𝐞𝐫𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/anesthesia-machinery-market-A06271

𝐔.𝐒. 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/us-digital-therapeutics-market-A06701

𝐅𝐞𝐫𝐭𝐢𝐥𝐢𝐭𝐲 𝐒𝐮𝐩𝐩𝐥𝐞𝐦𝐞𝐧𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/fertility-supplements-market-A07134

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com

Alied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.